Fusion Antibodies plc provided earnings guidance for the first half of fiscal year 2024. For the period, the company expects revenue to be behind current market expectations, at not less than £541,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 GBX | -7.25% | -4.48% | -24.71% |
05-23 | Celadon ships to US; Oxford BioDynamics-Goodbody pact | AN |
05-23 | Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.71% | 4.17M | |
+34.01% | 51.07B | |
+33.84% | 38.86B | |
-8.02% | 38.78B | |
-8.98% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- FAB Stock
- News Fusion Antibodies plc
- Fusion Antibodies plc Provides Earnings Guidance for the First Half of Fiscal Year 2024